Pathological Outcomes in Kidney and Brain in Male Fischer Rats Given Dietary Ochratoxin A, Commencing at One Year of Age

por Mantle, Peter G., Nolan, Christopher C.
Publicado 2010

Biological Characteristics and Clinical Outcome of Triple Negative Primary Breast Cancer in Older Women – Comparison with Their Younger Counterparts

por Syed, Binafsha M., Green, Andrew R., Nolan, Christopher C., Morgan, David A. L., Ellis, Ian O., Cheung, Kwok-Leung
Publicado 2014

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers

por Aleskandarany, Mohammed, Caracappa, Daniela, Nolan, Christopher C., Macmillan, R. Douglas, Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Publicado 2015

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes

por El Ansari, Rokaya, Craze, Madeleine L., Diez-Rodriguez, Maria, Nolan, Christopher C., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Publicado 2018

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours

por El Ansari, Rokaya, Craze, Madeleine L., Miligy, Islam, Diez-Rodriguez, Maria, Nolan, Christopher C., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Publicado 2018

Biological and clinical significance of PARP1 protein expression in breast cancer

por Green, Andrew R., Caracappa, Daniela, Benhasouna, Ahmed A., Alshareeda, Alaa, Nolan, Christopher C., Macmillan, R. Douglas, Madhusudan, Srinivasan, Ellis, Ian O., Rakha, Emad A.
Publicado 2014

Phenotypic characterisation of breast cancer: the role of CDC42

por Chrysanthou, Eleni, Gorringe, Kylie L., Joseph, Chitra, Craze, Madeleine, Nolan, Christopher C., Diez-Rodriguez, Maria, Green, Andrew R., Rakha, Emad A., Ellis, Ian O., Mukherjee, Abhik
Publicado 2017

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer

por Green, Andrew R., Barros, Fabrício F. T., Abdel-Fatah, Tarek M. A., Moseley, Paul, Nolan, Christopher C., Durham, Alice C., Rakha, Emad A., Chan, Stephen, Ellis, Ian O.
Publicado 2014

Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women

por Agboola, Ayodeji O. J., Banjo, Adekumbiola A. F., Anunobi, Charles C., Salami, Babatunde, Agboola, Mopelola Deji, Musa, Adewale A., Nolan, Christopher C., Rakha, Emad A., Ellis, Ian O., Green, Andrew R.
Publicado 2013

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

por Green, Andrew R, Aleskandarany, Mohammed A, Agarwal, Devika, Elsheikh, Somaia, Nolan, Christopher C, Diez-Rodriguez, Maria, Macmillan, R Douglas, Ball, Graham R, Caldas, Carlos, Madhusudan, Srinivasan, Ellis, Ian O, Rakha, Emad A
Publicado 2016

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes

por Joseph, Chitra, Macnamara, Olivia, Craze, Madeleine, Russell, Roslin, Provenzano, Elena, Nolan, Christopher C., Diez-Rodriguez, Maria, Sonbul, Sultan N., Aleskandarany, Mohammed A., Green, Andrew R., Rakha, Emad A., Ellis, Ian O., Mukherjee, Abhik
Publicado 2018

MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer

por Craze, Madeleine L, Cheung, Hayley, Jewa, Natasha, Coimbra, Nuno D M, Soria, Daniele, El-Ansari, Rokaya, Aleskandarany, Mohammed A, Wai Cheng, Kiu, Diez-Rodriguez, Maria, Nolan, Christopher C, Ellis, Ian O, Rakha, Emad A, Green, Andrew R
Publicado 2018

Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series

por Green, Andrew R, Soria, Daniele, Stephen, Jacqueline, Powe, Desmond G, Nolan, Christopher C, Kunkler, Ian, Thomas, Jeremy, Kerr, Gillian R, Jack, Wilma, Cameron, David, Piper, Tammy, Ball, Graham R, Garibaldi, Jonathan M, Rakha, Emad A, Bartlett, John MS, Ellis, Ian O
Publicado 2016

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment

por Abdel-Fatah, Tarek M. A., Broom, Reuben J., Lu, Jun, Moseley, Paul M., Huang, Baiqu, Li, Lili, Liu, Suling, Chen, Longxin, Ma, Runlin Z., Cao, Wenming, Wang, Xiaojia, Li, Yan, Perry, Jo K., Aleskandarany, Mohammed, Nolan, Christopher C., Rakha, Emad A., Lobie, Peter E., Chan, Stephen Y. T., Ellis, Ian O., Hwang, Le-Ann, Lane, David P., Green, Andrew R., Liu, Dong-Xu
Publicado 2019